DNA Topoisomerase IIα and Breast Cancer Chemotherapy Response
Author Information
Author(s): MacGrogan G, Rudolph P, Mascarel I de, Mauriac L, Durand M, Avril A, Dilhuydy J M, Robert J, Mathoulin-Pélissier S, Picot V, Floquet A, Sierankowski G, Coindre J M
Primary Institution: Institut Bergonié
Hypothesis
The study aims to analyze the effect of Topo IIα expression on the response to primary chemotherapy in breast cancer patients.
Conclusion
Higher levels of Topo IIα expression are associated with better responses to anthracycline-based chemotherapy in breast cancer patients.
Supporting Evidence
- High expression of Ki-S7 (>15%) was associated with tumor regression ≥50%.
- Ki-S7 positivity ranged from 0 to 50% with a median value of 15%.
- Patients' ages ranged from 31 to 70 years, with a mean of 53 years.
Takeaway
This study found that breast cancer tumors with more Topo IIα protein responded better to chemotherapy, which helps doctors choose the right treatment.
Methodology
Immunohistochemical detection of Topo IIα was performed on tumor core biopsies from patients treated with primary chemotherapy.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific patient population analyzed.
Limitations
The study was limited to a specific cohort and may not generalize to all breast cancer patients.
Participant Demographics
Patients were aged 31 to 70 years, with a mean age of 53 and a median age of 55.
Statistical Information
P-Value
0.004
Confidence Interval
1.3–6.4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website